US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Patent 11116820 was granted and assigned to Eiger BioPharmaceuticals on September, 2021 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
April 17, 2020
0
Date of Patent
September 14, 2021
0
Patent Applicant
Patent Application Number
20200417
0
Patent Citations Received
Patent Inventor Names
Xiaofeng Xiong
0
Patent Jurisdiction
Patent Number
Find more entities like US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.